The global in-vitro toxicology testing market size is expected to reach USD 64.81 billion by 2030, registering a CAGR of 11.17% from 2024 to 2030, according to a new report by Grand View Research, Inc. Over the years, acceptance of in-vitro toxicology testing methods by regulatory authorities is increasing at a faster pace & thus validation of these tests methods opposed to conventional testing is even rising. Also, development of technologies to substitute animal use for toxicology tests has fueled the usage of in-vitro models such as in-silico simulation, assays, 3D cell cultures and many more, thereby boosting market growth.
Screening of a new drug candidate involves the use of animals for preclinical studies which is very tedious and expensive. However, in recent times, several jurisdictions are promoting ban for animal-based chemical testing. For example, for several years, the EU has been promoting the reduction, replacement, and refinement of animal tests. The Regulation on cosmetic products (1223/2009), REACH (2007/2006), the Directive on the protection of animals used for scientific purposes (2010/63), and Classification, Labelling and Packaging (CLP) (1272/2008) are some examples of EU legislation that are engaged in strongly encouraging the replacement of animal toxicology testing. Furthermore, in June 2018, the Cruelty-Free Cosmetics Act was passed in California to ban the selling of animal-tested products after 2020.
Many governments and private organization are taking actions to minimize conventional testing models, providing funds to support & develop in-vitro toxicology assays and form conducive government policies. Thus, increase in government initiatives that are focused on banning animal testing can be attributed to the rise in adoption of in-vitro toxicological models and creates many opportunities within the market. For instance, approximately USD 3.2 million were contributed by People for the Ethical Treatment of Animals (PETA) and its international associates to promote the development of non-animal test methods.
The advancements in computational and screening methods such as biological, high throughput, and chemical coupled with the vast number of public databases for toxicity analysis has expanded largely. This has allowed researchers to access information for drug discovery studies, toxicology profiling, and drug development programs. For instance, the MetaTox HS project by Agilent Technologies, Inc. brings advanced solutions for toxicity assays & high sensitivity metabolism during drug development procedures.
Request a free sample copy or view report summary: In-vitro Toxicology Testing Market Report
Based on technology, Cell culture technology segment held a dominant market share of 43.88% in the global market in 2023, owing to the increased demand for accurate & cost-effective analysis. Moreover, the adoption of 3D cell culture is also propelling the growth of this segment
On the basis of application, the systemic toxicology application segment dominated the market in 2023. Generation of toxicology data points such as minimum dose, tolerated dose, risk assessment and many more will contribute to the revenue generation
The cellular assay accounted for the largest share in terms of revenue and is expected to grow over the forecasted period, owing to the developments in cell-based imaging assays, high throughput screening & label-free detection
The pharmaceutical industry end-use segment held a major share in the market in 2023. The importance of toxicology testing during drug development stages coupled with high number of product pipeline attributes to the revenue generation
North America dominated the market and accounted for a 47.73% share in 2023 due to prevalence of animal testing bans & supportive government initiatives for toxicology research. In addition, aggregation of players in this regions to provide in-vitro testing product and services will continue the revenue generation during the forecast
Grand View Research has segmented the global in-vitro toxicology testing market on the basis of on product, application, method, technology, end-use, and region:
In-vitro Toxicology Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)
Cell Culture Technology
High Throughput Technology
Molecular Imaging Technology
OMICS Technology
In-vitro Toxicology Testing Product Outlook (Revenue, USD Million, 2018 - 2030)
Consumables
Assays
Instruments
Software
Services
In-vitro Toxicology Testing Method Outlook (Revenue, USD Million, 2018 - 2030)
Cellular Assay
Live Cells
High Throughput / High Content Screening
Molecular Imaging
Confocal Microscopy
Others
Others
Fixed Cells
Biochemical Assay
In Silico
Ex-vivo
In-vitro Toxicology Testing Application Outlook (Revenue, USD Million, 2018 - 2030)
Systemic Toxicology
Acute Toxicity
Carcinogenicity
Developmental Toxicity
Others
Dermal Toxicity
Skin Irritation Test
Skin Sensitization Test
Skin Corrosion Test
Phototoxicity Test
Others
Endocrine Disruption
Dioxins
Phthalates
Polychlorinated biphenyls (PCB)
Ocular Toxicity
Intravitreal
Subretinal
Others
Others
Immunotoxicity
Reproductive Toxicity
Neurotoxicity
Epigenetic Alterations
Genotoxicity
Others
In-vitro Toxicology Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Industry
Cosmetics & Household Products
Academic Institutes & Research Laboratories
Diagnostics
Medical Devices
Others
Chemicals Industry
Food Industry
In-vitro Toxicology Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the In-vitro Toxicology Testing Market
Charles River Laboratories International, Inc.
SGS S.A.
Merck KGaA
Eurofins Scientific
Abbott Laboratories
Laboratory Corporation of America Holdings
Evotec S.E.
Thermo Fisher Scientific, Inc.
Quest Diagnostics Incorporated
Agilent Technologies, Inc.
Catalent, Inc.
Danaher Corporation
Bio-Rad Laboratories, Inc.
BioIVT
Gentronix
"The quality of research they have done for us has been excellent..."